Time to HCT from initial therapy
| . | D-to-transplant . | P value . | |
|---|---|---|---|
| N . | Median (range) . | ||
| Whole cohort | 147 | 118 (58, 621) | |
| Age at treatment | |||
| <60 | 93 | 114 (58, 453) | − |
| 60-75 | 54 | 130.5 (65, 621) | .17 |
| Sex | |||
| Female | 75 | 117 (58, 621) | − |
| Male | 72 | 119.5 (65, 549) | .89 |
| Race | |||
| White | 102 | 121.5 (58, 621) | − |
| Black | 32 | 112 (75, 281) | .80 |
| Asian | 11 | 165 (59, 358) | .67 |
| Ethnicity | |||
| Non-Hispanic | 129 | 118 (58, 621) | − |
| Hispanic | 18 | 118 (90, 453) | .86 |
| Diagnosis | |||
| AML | 93 | 111 (59, 621) | − |
| ALL | 45 | 136 (91, 549) | < .001 |
| MDS | 9 | 92 (58, 425) | .022 |
| Risk in AML patients | |||
| Intermediate | 34 | 113 (59, 358) | − |
| Poor | 59 | 111 (86, 621) | .76 |
| Donor type | |||
| MRD | 47 | 113 (58, 425) | − |
| MUD | 35 | 140 (83, 297) | .018 |
| HID | 65 | 113 (72, 621) | .74 |
| Pre-BMT status | |||
| CR1 | 122 | 118.7 (59, 621) | − |
| Other | 25 | 117 (58, 453) | .89 |
| . | D-to-transplant . | P value . | |
|---|---|---|---|
| N . | Median (range) . | ||
| Whole cohort | 147 | 118 (58, 621) | |
| Age at treatment | |||
| <60 | 93 | 114 (58, 453) | − |
| 60-75 | 54 | 130.5 (65, 621) | .17 |
| Sex | |||
| Female | 75 | 117 (58, 621) | − |
| Male | 72 | 119.5 (65, 549) | .89 |
| Race | |||
| White | 102 | 121.5 (58, 621) | − |
| Black | 32 | 112 (75, 281) | .80 |
| Asian | 11 | 165 (59, 358) | .67 |
| Ethnicity | |||
| Non-Hispanic | 129 | 118 (58, 621) | − |
| Hispanic | 18 | 118 (90, 453) | .86 |
| Diagnosis | |||
| AML | 93 | 111 (59, 621) | − |
| ALL | 45 | 136 (91, 549) | < .001 |
| MDS | 9 | 92 (58, 425) | .022 |
| Risk in AML patients | |||
| Intermediate | 34 | 113 (59, 358) | − |
| Poor | 59 | 111 (86, 621) | .76 |
| Donor type | |||
| MRD | 47 | 113 (58, 425) | − |
| MUD | 35 | 140 (83, 297) | .018 |
| HID | 65 | 113 (72, 621) | .74 |
| Pre-BMT status | |||
| CR1 | 122 | 118.7 (59, 621) | − |
| Other | 25 | 117 (58, 453) | .89 |